• Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide’s fully diluted share capital (excluding therefrom any treasury shares) at CHF 44.31 per share, representing an equity value of approximately CHF 1.46 billion.
• Strong transaction support, with a unanimous recommendation from PolyPeptide’s Board members (acting through its independent and non-conflicted members) and an irrevocable tender undertaking from PolyPeptide’s largest shareholder, representing approximately 55.65% of outstanding shares (excluding treasury shares).
• PolyPeptide’s specialized peptide expertise and global multi-site network to strengthen Samsung Biologics’ multi-modality and global manufacturing excellence
• Strategic investment to propel Samsung Biologics’ long-term growth strategy spanning portfolio, geography, and capacity

INCHEON, South Korea, July 20, 2026 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS) today announced the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group AG (“PolyPeptide”) (ISIN CH1110760852, ticker symbol: PPGN), a leading global contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs).

Under the terms of the offer, PolyPeptide shareholders will receive CHF 44.31 in cash for each PolyPeptide share, representing an implied equity value of approximately CHF 1.46 billion. The transaction is expected to be completed towards the end of 2026, subject to customary offer conditions, including a minimum acceptance threshold of 66⅔%, applicable regulatory approvals, and other conditions described in the pre-announcement published today (Link), and the offer prospectus to be published in accordance with Swiss takeover law.

After a comprehensive review of strategic options, PolyPeptide’s Board of Directors, acting through its independent and non-conflicted members, unanimously recommend that PolyPeptide shareholders accept the tender offer, subject to the terms and conditions set forth in the offer prospectus. The Board determined that the transaction represents an attractive outcome for shareholders and PolyPeptide while positioning PolyPeptide for its next phase of growth as part of Samsung Biologics’ global CDMO platform.

With this transaction, Samsung Biologics will expand its capabilities beyond antibodies and ADCs to include peptide therapeutics, one of the fastest-growing segments of the biopharmaceutical industry, driven by surging global demand for obesity treatments and the continued expansion of peptide-based therapies into new disease areas. The transaction brings together Samsung Biologics’ global manufacturing scale with PolyPeptide’s specialized peptide expertise to create a differentiated, end-to-end multi-modality CDMO platform. PolyPeptide stands as one of the industry’s top peptide CDMOs, distinguished by its advanced technology platform and proven track record, with more than 70 years of API manufacturing heritage and over 1,000 therapeutic peptides produced to date.

PolyPeptide operates an integrated development-to-commercial model with growth focused on a modular, automation approach, giving it the flexibility to adapt quickly to changing market demand. Through PolyPeptide’s peptide capabilities, innovative technologies, and proven commercial manufacturing track record, Samsung Biologics aims to serve clients across a broader range of therapeutic modalities by addressing growing demand for peptide-based therapeutics, particularly in obesity and diabetes, including GLP-1 therapies, while advancing innovation across high-growth areas such as oncology and other emerging indications.

The planned acquisition extends beyond adding capacity; it lays the foundation for Samsung Biologics’ next phase of growth, supported by a strong pipeline of active peptide projects that includes a deep late-stage portfolio. PolyPeptide operates global sites across Sweden, Belgium, France, the United States, India, together with a corporate office in Switzerland and a separate Innovation Center in Strasbourg, France, with capabilities encompassing R&D, development, and commercial manufacturing.

Upon completion of the transaction, Samsung Biologics will bring together PolyPeptide’s highly experienced team and specialized peptide expertise, further enhancing its capabilities. By combining the companies’ scientific strengths, manufacturing excellence, and global operations, the transaction is expected to enhance operational excellence, unlock additional growth opportunities, and further strengthen Samsung Biologics’ position as a leading global multi-modality CDMO.

“This acquisition reinforces our long-term growth strategy by not only broadening our service portfolio with modality expansion into peptides including GLP-1, but by also boosting our geographic reach and proximity further within the US, Europe, and India,” said John Rim, Chairman of the Board of Directors and CEO of Samsung Biologics. “We highly value PolyPeptide’s world-class employees, industry-leading capabilities, and global operational footprint, and look forward to leveraging the complementary strengths of PolyPeptide and Samsung Biologics in our continued growth supporting clients as the CDMO of choice for decades to come.”

“PolyPeptide was built on the dedication of our employees, deep scientific expertise and strong customer focus. After a comprehensive review of strategic options, the Board is convinced that Samsung Biologics’ offer is compelling for our shareholders, delivering an attractive cash price and immediate, certain value today,” said Peter Wilden, Chairman of the Board of Directors of PolyPeptide. “At the same time, it represents a transformational opportunity to accelerate our strategic ambitions at a scale we could not reach alone – creating a stronger global partner for customers and a platform uniquely positioned to lead the next phase of growth in peptide-based therapeutics.”

Samsung Biologics is launching an all-cash public tender offer for all publicly held shares in PolyPeptide. The Offer Price represents a 40% premium to the undisturbed share price of CHF 31.65 (the “Unaffected Price”), being the last closing price of PolyPeptide’s shares on the SIX Swiss Exchange (“SIX”) as of 10 April 2026, which was the last trading day prior to the emergence of market rumors regarding a potential acquisition of PolyPeptide. The Offer Price represents an approximately 11.6% premium to the volume-weighted average share price over the last 60 trading days prior to the publication of this announcement. The Board of Directors of PolyPeptide, acting through its independent and non-conflicted members, unanimously recommends that shareholders accept the offer. The transaction is further supported by PolyPeptide’s largest shareholder, who holds approximately 55.65% (based on total shares, excluding therefrom any treasury shares) and who has undertaken to tender all of its shares into the offer.

Indicative timeline
The offer by Samsung Biologics is conditioned upon at least two-thirds of all PolyPeptide shares on a fully diluted basis being tendered into the offer at the end of the offer period, together with other customary offer conditions, including the regulatory approvals set out in the pre-announcement.

The tender offer is expected to be launched by the end of August 2026 by publication of the formal offer prospectus and will remain open for a minimum of twenty trading days on the SIX Swiss Exchange (“SIX”), following a ten trading-day cooling-off period under Swiss takeover law. The pre-announcement, published together with this press release, sets out the tender offer procedure and the specific terms and conditions of the offer.

Once the offer has been successfully completed, Samsung Biologics intends to pursue a squeeze-out of any remaining minority shares and to delist PolyPeptide from the SIX, at which point PolyPeptide would become a wholly owned subsidiary of Samsung Biologics.

J.P. Morgan is acting as exclusive financial advisor to Samsung Biologics, with Ernst & Young Han Young serving as accounting and tax advisor. O’Melveny & Myers LLP and Schellenberg Wittmer Ltd are acting as legal advisors to Samsung Biologics.

About Samsung Biologics Co., Ltd.
Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 from the acquisition of a manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. Samsung Biologics has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities.

Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.

By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.

Samsung Biologics’ global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. Samsung Biologics is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, please visit https://samsungbiologics.com/.

Media Contacts
Samsung Biologics
[Claire Kim / cair.kim@samsung.com]

Investor Contacts
Samsung Biologics
[Jaewan Jun / jae.jun@samsung.com]

For additional information about the offer, please visit https://samsungbiologics.com/offer.

About PolyPeptide
PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.

Disclosure Notice
The pre-announcement of the offer, which has been published today, is available at https://samsungbiologics.com/offer.

The public tender offer is subject to customary terms and conditions as well as regulatory approvals and is currently expected to be completed by the end of 2026.

This publication does not constitute a prospectus or a similar notice according to articles 35 et seqq. and 69 of the Swiss Financial Services Act, is for information purposes only and does not constitute an offer document or an offer of securities for purchase or subscription, nor a solicitation of an offer to buy or subscribe for securities, in any jurisdiction. The terms and conditions of the tender offer will be set out exclusively in the offer prospectus to be published in accordance with applicable Swiss takeover law, including the Swiss Financial Market Infrastructure Act and the Takeover Ordinance. Investors and holders of PolyPeptide shares are advised to carefully read the pre-announcement and the offer prospectus, as well as all other documents relating to the tender offer, once available, as they will contain important information about the offer. These documents will be made available in accordance with applicable law.

Offer Restrictions
General
The public tender offer for the registered shares with a nominal value of CHF 0.01 each (each a PolyPeptide Group Share) of PolyPeptide as described in the documents available on this website (the Offer) will not be made, directly or indirectly, in any country or jurisdiction in which it would be unlawful or otherwise violate any applicable laws or regulations, or which would require Samsung Biologics, Ltd., Incheon, Republic of Korea, (Samsung Biologics) or any of its direct and indirect subsidiaries launching the Offer, (the Offeror) to change or amend the terms or conditions of the Offer in any way, to make an additional filing with any governmental, regulatory or other authority or take additional action in relation to the Offer. It is not intended to extend the Offer to any such country or jurisdiction. Any document relating to the Offer must neither be distributed in any such country or jurisdiction nor be sent into such country or jurisdiction, and must not be used for the purpose of soliciting the purchase of securities of PolyPeptide by any person or entity resident or incorporated in any such country or jurisdiction. Terms and conditions of the Offer have been and/or will be published in the Offer Documentation.

United States of America
The Offer will be made in the U.S. pursuant to Section 14(e) of, and Regulation 14E under, the U.S. Securities Exchange Act of 1934, as amended (the U.S. Exchange Act), subject to the exemptions provided by Rule 14d-1(c) under the U.S. Exchange Act (the Tier I Exemption) and Rule 14e-5(b)(10) under the U.S. Exchange Act and any exemptions that may be granted by the U.S. Securities and Exchange Commission (SEC), and otherwise in accordance with the requirements of Swiss law. Accordingly, the Offer will be subject to disclosure and other procedural requirements, including with respect to withdrawal rights, settlement procedures and timing of payments that are different from those applicable under U.S. domestic tender offer procedures and laws.

Any financial statements or figures included or referenced in the offer prospectus have been or will be prepared in accordance with the applicable accounting standards of, or recognized in, Switzerland and/or the Republic of Korea, which may not be comparable to the financial statements of U.S. companies.

In accordance with the laws of Switzerland and subject to applicable regulatory requirements, Samsung Biologics and its subsidiaries (including the Offeror) and affiliates or their respective nominees or brokers (acting as agents for the Offeror) may from time to time after the date of the offer prospectus, and other than pursuant to the Offer, directly or indirectly, purchase or arrange to purchase PolyPeptide Group Shares or any securities that are convertible into, exchangeable for or exercisable for PolyPeptide Group Shares from their holders who are willing to sell them outside the Offer from time to time, including purchases in the open market at prevailing prices or in private transactions at negotiated prices, and shall comply with applicable laws and regulations in Switzerland and applicable U.S. securities laws, rules and regulations, including Rule 14e-5 under the U.S. Exchange Act (subject to the exemptions provided by Rule 14e-5(b)(10) under the U.S. Exchange Act). Any such purchases will not be made at prices higher than the offer price or on terms financially more favorable than those offered pursuant to the Offer, unless the offer price is increased accordingly. Any information about such purchases or arrangements to purchase will be publicly disclosed in the U.S. on offer website if and to the extent that such information is made public in accordance with the applicable laws and regulations of Switzerland. In addition, the financial advisor to PolyPeptide and, subject to applicable Swiss and U.S. securities laws, rules and regulations, including Rule 14e-5 under the U.S. Exchange Act (subject to the exemptions provided by Rule 14e-5(b)(10) under the U.S. Exchange Act), the financial advisor to Samsung Biologics and its subsidiaries (including the Offeror) and affiliates may also engage in ordinary course trading activities in securities of PolyPeptide, which may include purchases or arrangements to purchase such securities.

It may be difficult for holders of Company Shares in the U.S. (U.S. Holders) to enforce their rights and any claim they may have arising out of U.S. securities laws, since the Offeror and PolyPeptide are located in a non-U.S. jurisdiction, and some or all of their officers and directors may be residents of a non-U.S. jurisdiction. U.S. Holders may not be able to sue a non-U.S. company or its officers or directors in a U.S. or non-U.S. court for violations of the U.S. securities laws. Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court’s judgment.

The receipt of cash pursuant to the Offer by a U.S. Holder may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local laws, as well as foreign and other tax laws. Each shareholder of PolyPeptide is urged to consult his or her independent professional advisor immediately regarding the tax consequences of an acceptance of the Offer.

Neither the SEC nor any securities commission of any State of the U.S. has (a) approved or disapproved of the Offer; (b) passed upon the merits or fairness of the Offer; or (c) passed upon the adequacy or accuracy of the disclosure in this Pre-Announcement. Any representation to the contrary is a criminal offence in the U.S.

U.S. Holders are encouraged to consult with their own legal (including with respect to Swiss law), financial and tax advisors regarding the Offer.

United Kingdom
The communication about this Offer is not being made by, and has not been approved by, an authorised person for the purposes of Section 21 of the Financial Services and Markets Act 2000, as amended. In the United Kingdom (U.K.), this communication and any other documents relating to the Offer is/will be directed only at persons (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the Order), (ii) falling within article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Order or (iii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as “relevant persons”). No communication in respect of the Offer must be acted on or relied on in the U.K. by persons who are not relevant persons. The Offer and any investment or investment activity to which this communication relates is / will be available in the U.K. to relevant persons only and will be engaged in only with relevant persons.

Australia, Canada and Japan
The Offer will not be addressed to shareholders of PolyPeptide whose place of residence, seat or habitual abode is in Australia, Canada, or Japan, and such shareholders may not accept the Offer.

Forward Looking Statements
This announcement contains forward-looking statements that reflect Samsung Biologics’ current expectations and views of future events. These statements can often be identified by terms such as “expect,” “intend,” “plan,” “anticipate,” “target,” “believe,” “will” and similar expressions. They include, among other things, statements relating to the expected timing, structure and completion of the tender offer; the anticipated benefits and synergies of the proposed transaction; and the future business, operations, financial performance and strategy of Samsung Biologics and PolyPeptide.

These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond Samsung Biologics’ control, that could cause actual results to differ materially from those expressed or implied. Such factors include, among others, the satisfaction of the conditions to the tender offer, the receipt of required regulatory approvals, the level of acceptance of the offer by PolyPeptide shareholders, the ability to successfully integrate PolyPeptide’s business, developments in the peptide and broader CDMO markets, and general economic and market conditions. No assurance can be given that the transactions described herein will be completed or as to the final terms.

Forward-looking statements speak only as of the date of this announcement and are based on information currently available to Samsung Biologics. Except as required by applicable law, Samsung Biologics undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SHANGHAI, July 19, 2026 /PRNewswire/ — Pudu Robotics, a global leader in commercial service robotics, is showcasing its full portfolio of intelligent robotics solutions at the 2026 World Artificial Intelligence Conference (WAIC), held from July 17–20 in Shanghai. A key highlight of this year’s exhibition is the offline global debut of the PUDU D7, Pudu’s next-generation semi-humanoid robot. In tandem with its exhibition highlights, Pudu Robotics was also honored with the 36Kr “Most Investor-Attractive AI & Embodied Intelligence Enterprise” Award, recognizing the company’s growing influence in the embodied AI sector and continued confidence from the investment community.

Full Product Matrix on Display: Demonstrating Multi-Scenario Capabilities

Pudu’s comprehensive presentation at WAIC 2026 showcased its complete technical and product layout, spanning service delivery, commercial cleaning, industrial delivery, and general embodied intelligence.

The PUDU D5 quadruped robot demonstrates advanced terrain adaptability and autonomous navigation across an on-site obstacle course mimicking sand, gravel, steps, and slopes, simulating autonomous inspections in complex environments such as power substations and industrial parks. Additionally, the D5 performed high-speed “drifting” demonstrations at the booth, reaching peak speeds of up to 5 m/s and showcasing industry-leading mobility and responsiveness.

Making its global offline public debut, the PUDU D7 engaged visitors with several immersive and interactive live experiences. Attendees posed for photos with the D7, instantly receiving unique snapshots taken directly from a “robotics perspective.” The robot also demonstrated advanced multi-robot coordination by autonomously walking and guiding the PUDU D5 quadruped around the booth while seamlessly avoiding pedestrian traffic, vividly illustrating collaborative workflows between different robotic form factors.

Pudu is also exhibiting its mature commercial robotics portfolio, including the BellaBot service delivery robot, the PUDU T300 industrial delivery robot, and the PUDU MT1 Max and PUDU CC1 Pro commercial cleaning robots. Together, these products highlight Pudu’s proven deployments across hospitality, retail, F&B, manufacturing, warehousing, and other industries.

Winning the “Most Investor-Attractive Enterprise” Award Amid Sustained Capital Traction

The “Most Investor-Attractive Enterprise” award from 36Kr arrives alongside sustained backing from major global institutional investors. In April 2026, Pudu Robotics completed a new financing round of nearly USD 150 million, bringing its valuation to more than USD 1.5 billion. This brings Pudu’s cumulative funding to more than USD 300 million.

This strong capital interest is supported by concrete commercial performance. According to the “2025 Global Embodied Intelligence and Commercial Service Robotics Independent Market Research Report” released by Frost & Sullivan, Pudu Robotics accounts for 25% and 23% of the global commercial service robotics market in terms of revenue and shipments respectively, ranking No. 1 worldwide in both categories. Furthermore, Pudu Robotics has maintained a year-over-year revenue growth rate exceeding 100%, with international markets accounting for more than 80% of total revenue for consecutive years. While the broader Embodied AI industry remains in early exploratory phases, Pudu has approached a positive EBITDA, achieving large-scale commercial viability ahead of the market.

From Product Export to Ecosystem Integration: A Blueprint for Global Expansion

According to the Research Report on Chinese Enterprises’ Overseas Expansion from 2025 to 2026 published by the 36Kr Research Institute, Pudu Robotics was featured as a primary benchmark case study for Embodied AI. The report attributes Pudu’s international success to its systematic combination of technological innovation, product capabilities, and localized global operation. Analysts noted that Pudu has successfully transitioned from exporting products to exporting global brand equity and integrated robotics ecosystems, establishing a core reference blueprint for hard-tech global expansion.

By deploying versatile product forms that span specialized, semi-humanoid, and humanoid forms, Pudu Robotics continues to focus on integrating Embodied AI directly into real-world environments—transforming Physical AI from a technical concept into a practical productivity partner.

About Pudu Robotics

Pudu Robotics, a global leader in the commercial service robotics sector, is dedicated to empowering easier work and better lives through AI and robotics, with a vision of building a global intelligent robotics infrastructure that serves 10 billion people worldwide.

Pudu Robotics has developed key core technologies and components, including robotic joint modules and motion controllers, and has filed more than 1,900 patent applications worldwide. Built on three core technologies—Embodied Navigation, Embodied Manipulation, and Embodied Interaction—Pudu Robotics has pioneered a “One Brain, Multiple Embodiments” architecture, establishing a comprehensive product portfolio that includes specialized, semi-humanoid, and humanoid robots.

Currently, Pudu offers four major product lines: service delivery, commercial cleaning, industrial delivery and general embodied AI. Its solutions are widely deployed across industries such as retail, hospitality, manufacturing, real estate and property services, healthcare, entertainment and sport, education, and public services.

To date, Pudu Robotics has shipped over 130,000 units globally, with a presence in more than 85 countries and regions.

SHANGHAI, July 19, 2026 /PRNewswire/ — Pudu Robotics, a global leader in commercial service robotics, is showcasing its full portfolio of intelligent robotics solutions at the 2026 World Artificial Intelligence Conference (WAIC), held from July 17–20 in Shanghai. A key highlight of this year’s exhibition is the offline global debut of the PUDU D7, Pudu’s next-generation semi-humanoid robot. In tandem with its exhibition highlights, Pudu Robotics was also honored with the 36Kr “Most Investor-Attractive AI & Embodied Intelligence Enterprise” Award, recognizing the company’s growing influence in the embodied AI sector and continued confidence from the investment community.

Full Product Matrix on Display: Demonstrating Multi-Scenario Capabilities

Pudu’s comprehensive presentation at WAIC 2026 showcased its complete technical and product layout, spanning service delivery, commercial cleaning, industrial delivery, and general embodied intelligence.

The PUDU D5 quadruped robot demonstrates advanced terrain adaptability and autonomous navigation across an on-site obstacle course mimicking sand, gravel, steps, and slopes, simulating autonomous inspections in complex environments such as power substations and industrial parks. Additionally, the D5 performed high-speed “drifting” demonstrations at the booth, reaching peak speeds of up to 5 m/s and showcasing industry-leading mobility and responsiveness.

Making its global offline public debut, the PUDU D7 engaged visitors with several immersive and interactive live experiences. Attendees posed for photos with the D7, instantly receiving unique snapshots taken directly from a “robotics perspective.” The robot also demonstrated advanced multi-robot coordination by autonomously walking and guiding the PUDU D5 quadruped around the booth while seamlessly avoiding pedestrian traffic, vividly illustrating collaborative workflows between different robotic form factors.

Pudu is also exhibiting its mature commercial robotics portfolio, including the BellaBot service delivery robot, the PUDU T300 industrial delivery robot, and the PUDU MT1 Max and PUDU CC1 Pro commercial cleaning robots. Together, these products highlight Pudu’s proven deployments across hospitality, retail, F&B, manufacturing, warehousing, and other industries.

Winning the “Most Investor-Attractive Enterprise” Award Amid Sustained Capital Traction

The “Most Investor-Attractive Enterprise” award from 36Kr arrives alongside sustained backing from major global institutional investors. In April 2026, Pudu Robotics completed a new financing round of nearly USD 150 million, bringing its valuation to more than USD 1.5 billion. This brings Pudu’s cumulative funding to more than USD 300 million.

This strong capital interest is supported by concrete commercial performance. According to the “2025 Global Embodied Intelligence and Commercial Service Robotics Independent Market Research Report” released by Frost & Sullivan, Pudu Robotics accounts for 25% and 23% of the global commercial service robotics market in terms of revenue and shipments respectively, ranking No. 1 worldwide in both categories. Furthermore, Pudu Robotics has maintained a year-over-year revenue growth rate exceeding 100%, with international markets accounting for more than 80% of total revenue for consecutive years. While the broader Embodied AI industry remains in early exploratory phases, Pudu has approached a positive EBITDA, achieving large-scale commercial viability ahead of the market.

From Product Export to Ecosystem Integration: A Blueprint for Global Expansion

According to the Research Report on Chinese Enterprises’ Overseas Expansion from 2025 to 2026 published by the 36Kr Research Institute, Pudu Robotics was featured as a primary benchmark case study for Embodied AI. The report attributes Pudu’s international success to its systematic combination of technological innovation, product capabilities, and localized global operation. Analysts noted that Pudu has successfully transitioned from exporting products to exporting global brand equity and integrated robotics ecosystems, establishing a core reference blueprint for hard-tech global expansion.

By deploying versatile product forms that span specialized, semi-humanoid, and humanoid forms, Pudu Robotics continues to focus on integrating Embodied AI directly into real-world environments—transforming Physical AI from a technical concept into a practical productivity partner.

About Pudu Robotics

Pudu Robotics, a global leader in the commercial service robotics sector, is dedicated to empowering easier work and better lives through AI and robotics, with a vision of building a global intelligent robotics infrastructure that serves 10 billion people worldwide.

Pudu Robotics has developed key core technologies and components, including robotic joint modules and motion controllers, and has filed more than 1,900 patent applications worldwide. Built on three core technologies—Embodied Navigation, Embodied Manipulation, and Embodied Interaction—Pudu Robotics has pioneered a “One Brain, Multiple Embodiments” architecture, establishing a comprehensive product portfolio that includes specialized, semi-humanoid, and humanoid robots.

Currently, Pudu offers four major product lines: service delivery, commercial cleaning, industrial delivery and general embodied AI. Its solutions are widely deployed across industries such as retail, hospitality, manufacturing, real estate and property services, healthcare, entertainment and sport, education, and public services.

To date, Pudu Robotics has shipped over 130,000 units globally, with a presence in more than 85 countries and regions.